Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 48

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Diffuse large B-cell lymphoma refractory

Not yet recruiting

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Acute lymphocytic leukaemia

Not yet recruiting

Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pegaspargase
  • Sponsor:Assistance Publique Hopitaux De Paris

Adult T-cell lymphoma/leukaemia

Not yet recruiting

Study on Acalabrutinib and R-CHOP for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Swiss Group for Clinical Cancer Research

Non-Hodgkin's lymphoma

Not yet recruiting

Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga)
  • Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Haemophagocytic lymphohistiocytosis

Not yet recruiting

Gene Therapy Study for Familial Hemophagocytic Lymphohistiocytosis Using MUNC-CD34 and MUNC-T3 in Patients with UNC13D Gene Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Munc-Cd34
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute leukaemia+6

Not yet recruiting

Study on Triptorelin for Fertility Protection in Young Women and Teenagers Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Triptorelin
  • Sponsor:Karolinska University Hospital

Eosinophilic oesophagitis

Not recruiting

Title: Study of Solrikitug compared to placebo for adults with Eosinophilic Esophagitis to evaluate its effectiveness and safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Solrikitug
  • Sponsor:NI One Inc.

Coagulopathy

Not recruiting

Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Octapharma AG

Myelofibrosis

Not recruiting

Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

Acute lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.